Basiliximab (Simulect®) and Daclizumab (Zenapax®)

Nadim Mahmud, Burcin Taner, Nasimul Ahsan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

To function as effector cells, T cells must undergo antigen-stimulated activation that induces synthesis of many lymphokines, including interleukin-2 (IL-2). In certain diseases, a proportion of these stimulated cells will express surface interleukin-2 receptor (IL-2R) alpha peptide, and in these conditions the serum concentration of the soluble form of this peptide is frequently elevated. Such evidence of T cell activation and IL-2R expression appears in the setting of transplant rejections as well as in many neoplastic and autoimmune disorders, thus forming the basis for anti-IL-2-directed therapy in these conditions. In this chapter, we will discuss the potential therapies involving IL-2mAbs in organ transplant and other non-transplant immunologic conditions.

Original languageEnglish (US)
Title of host publicationApproved Therapeutic Antibodies
PublisherWiley-Blackwell
Pages1375-1404
Number of pages30
Volume3-4
ISBN (Electronic)9783527682423
ISBN (Print)9783527329373
DOIs
StatePublished - Dec 3 2014

Keywords

  • IL-2 receptor blockers
  • Immunologic diseases
  • Monoclonal antibodies
  • Solid organ
  • Transplantation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Basiliximab (Simulect®) and Daclizumab (Zenapax®)'. Together they form a unique fingerprint.

  • Cite this

    Mahmud, N., Taner, B., & Ahsan, N. (2014). Basiliximab (Simulect®) and Daclizumab (Zenapax®). In Approved Therapeutic Antibodies (Vol. 3-4, pp. 1375-1404). Wiley-Blackwell. https://doi.org/10.1002/9783527682423.ch47